Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım

KALKAN, Göknur

Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım

Göknur KALKAN (Ankara Yıldırım Beyazıt Üniversitesi)

Türkderm-Deri Hastalıkları ve Frengi Arşivi

2 0

Yıl: 2017 Cilt: 51 Sayı: 3 Sayfa Aralığı: 71 - 77 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım

Öz:

Tüm dünyada %2-3 oranında görülme sıklığına sahip psoriazis, geçmişte sadece deriye sınırlı kabul edilirken, günümüzde birçok komorbiditenin eşlik ettiği kronik sistemik enflamatuvar bir hastalık olarak ele alınmaktadır. Orta-şiddetli düzeyde psoriazisi olanlarda daha sık görülen komorbiditelerle ilgili çeşitli sınıflamalar mevcuttur. Basit olarak klasik, kronik sistemik enflamasyonla ilişkili, yaşam tarzı ile ilgili ve tedavi ile ilgili olarak sınıflanabileceği gibi medikal komorbiditeler, psikiyatrik/psikolojik komorbiditeler ve komorbiditelere katkı yapan durumlar şeklinde de sınıflanabilmektedir. Bu derlemede psoriazis ve eşlik eden komorbiditelerin gözden geçirilmesiyle; komorbiditelerin erken tanı ve tedavisini sağlama, komorbiditilerin erken tespitine yönelik geliştirilen tarama önerilerini öğrenme ve hastalığın yönetiminde entegre, multidisipliner yaklaşım ile uzun dönem hastalık kontrolü ve hayat kalitesinde düzelme sağlamak hedeflenmektedir.

Anahtar Kelime:

Konular: Dermatoloji

Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management

Öz:

Psoriasis, with a worldwide prevalence of 2-3%, is now assumed as a systemic chronic inflammatory disease accompanied by comorbidities while it was accepted as a disease limited only to the skin in the past. There are several classifications of the comorbidities which are more common in patients with moderate to severe psoriasis. Simply, comorbidities can be classified as classic, emerging, related to lifestyle, related to treatment. They can also be categorized as medical comorbidities, psychiatric/psychologic comorbidities, and behaviors contributing to medical and psychiatric comorbidities. In this review, providing early diagnosis and treatment of comorbidities, learning screening recommendations for early detection and long-term disease control and improvement in life quality by integrated, multidisciplinary approach were targeted.

Anahtar Kelime:

Konular: Dermatoloji

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Grozdev I, Korman N, Tsankov N: Psoriasis as a systemic disease. Clin Dermatol 2014;32:343-50.
2. Donigan JM: Focus on psoriasis: a report from the 73rd annual meeting of the American Academy of Dermatology. Psoriasis-related topics included targeted therapies, safety of biologies, comorbidities. J Clin Aesthet Dermatol 2015;8(Suppl 3):8-16.
3. Boehncke WH, Boehncke S: More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly 2014;144:w13968.
4. Oliveira Mde F, Rocha Bde O, Duarte GV: Psoriasis: classical and emerging comorbidities. An Bras Dermatol 2015;90:9-20.
5. Menter A, Gottlieb A, Feldman SR, et al: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50.
6. Farley E, Menter A: Psoriasis: comorbidities and associations. G Ital Dermatol Venereol 2011;146:9-15.
7. Boehncke WH, Qureshi A, Merola JF, et al: Diagnosing and treating psoriatic arthritis: an update. Br J Dermatol 2014;170:772-86.
8. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M: Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009;23:683-91.
9. Taylor W, Gladman D, Helliwell P, et al: Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
10. Duarte GV, Oliveira Mde F, Cardoso TM, et al: Association between obesity measured by different parameters and severity of psoriasis. Int J Dermatol 2013;52:177-81.
11. Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al: Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr 2014;105:31-44.
12. Ni C, Chiu MW: Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol 2014;7:119-32.
13. Dalamaga M, Papadavid E: Metabolic co-morbidities and psoriasis: The chicken or the egg? World J Dermatol 2013;2:32-5.
14. Armstrong AW, Harskamp CT, Armstrong EJ: The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012;2:e54.
15. Gerdes S, Rostami-Yazdi M, Mrowietz U: Adipokines and psoriasis. Exp Dermatol 2011;20:81-7.
16. Jensen P, Zachariae C, Christensen R, et al: Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol 2013;149:795-801.
17. de Menezes Ettinger JE, Azaro E, de Souza CA, et al: Remission of psoriasis after open gastric bypass. Obes Surg 2006;16:94-7.
18. Pérez-Pérez L, Allegue F, Caeiro JL, Zulaica JM: Severe psoriasis, morbid obesity and bariatric surgery. Clin Exp Dermatol 2009;34:421-2.
19. Naldi L, Addis A, Chimenti S, et al: Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008;217:365-73.
20. Metabolik sendrom kılavuzu. Türkiye Endokrinoloji ve Metabolizma Derneği 2009.
21. Armstrong AW, Harskamp CT, Armstrong EJ: Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013;68:654-62.
22. Akcali C, Buyukcelik B, Kirtak N, Inaloz S: Clinical and laboratory parameters associated with metabolic syndrome in Turkish patients with psoriasis. J Int Med Res 2014;42:386-94.
23. Aurangabadkar SJ: Comorbidities in psoriasis. Indian J Dermatol Venereol Leprol 2013;79(Suppl 7):10-7.
24. Armstrong AW, Harskamp CT, Armstrong EJ: Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013;149:84-91.
25. Armstrong AW, Guérin A, Sundaram M, et al: Psoriasis and risk of diabetesassociated microvascular and macrovascular complications. J Am Acad Dermatol 2015;72:968-77.
26. Farrokhi F, Taylor HC, McBride NM: Etanercept-induced hypoglycemia and improved glycemic control in a patient with type 2 diabetes. Endocr Pract 2011;17:306-7.
27. Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S: Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evid Based Med 2012;17:171-6.
28. Armstrong AW, Harskamp CT, Armstrong EJ: The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2013;31:433-42.
29. Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL: Psoriasis and hypertension severity: results from a case-control study. PLoS One 2011;6:e18227.
30. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW: The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol 2013;168:486-95.
31. Bacchetti T, Campanati A, Ferretti G, Simonetti O, Liberati G, Offidani AM: Oxidative stress and psoriasis: the effect of antitumour necrosis factor-? inhibitor treatment. Br J Dermatol 2013;168:984-9.
32. Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A: Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006;154:83-6.
33. Grossman RM, Delaney RJ, Brinton EA, Carter DM, Gottlieb AB: Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol 1991;25:648-51.
34. Shirinsky IV, Shirinsky VS: Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol 2007;57:529-31.
35. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG: Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009;145:700-3.
36. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735- 41.
37. Chiu HY, Chang WL, Huang WF, Wen YW, Tsai YW, Tsai TF: Increased risk of arrhythmia in patients with psoriatic disease: A nationwide population-based matched cohort study. J Am Acad Dermatol 2015;73:429-38.
38. Reich K: The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012;26(Suppl 2):3-11.
39. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M: Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459-67.
40. Balta I, Balta S, Demirkol S, et al: Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology 2014;65:74-8.
41. Osto E, Piaserico S, Maddalozzo A, et al: Impaired coronary flow reserve in young patients affected by severe psoriasis. Atherosclerosis 2012;221:113-7.
42. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-7.
43. Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G: Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006;155:1165-9.
44. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS: Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-7.
45. Wu JJ, Poon KY: Association of gender, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. J Am Acad Dermatol 2013;69:650-1.
46. Mehta NN, Yu Y, Pinnelas R, et al: Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011;124:775.
47. Parisi R, Rutter MK, Lunt M, et al: Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol 2015;135:2189-97.
48. Perk J, De Backer G, Gohlke H, et al: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.
49. Wohlrab J, Fiedler G, Gerdes S, et al: Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Arch Dermatol Res 2013;305:91-8.
50. Kimball AB, Gladman D, Gelfand JM, et al: National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42.
51. Radtke MA, Mrowietz U, Feuerhahn J, et al: Early detection of comorbidity in psoriazis: recommendations of the National Conference on Healthcare in Psoriasis. J Dtsch Dermatol Ges 2015;13:674-89.
52. Daudén E, Castañeda S, Suárez C, et al: Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2013;27:1387-404.
53. Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D: Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. Br J Dermatol 2014;170:366-73.
54. Brauchli YB, Jick SS, Miret M, Meier CR: Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol 2009;129:2604-12.
55. Gisondi P, Targher G, Zoppini G, Girolomoni G: Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:758-64.
56. Miele L, Vallone S, Cefalo C, et al: Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:778-86.
57. Kalb RE, Strober B, Weinstein G, Lebwohl M: Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37.
58. Wu JJ, Nguyen TU, Poon KY, Herrinton LJ: The association of psoriasis with autoimmune diseases. J Am Acad Dermatol 2012;67:924-30.
59. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA: Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000;123:1102-11.
60. Cohen AD, Dreiher J, Birkenfeld S: Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009;23:561-5.
61. Binus AM, Han J, Qamar AA, Mody EA, Holt EW, Qureshi AA: Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol 2012;26:644-50.
62. Wu JJ, Nguyen TU, Poon KY, Herrinton LJ: The association of psoriasis with autoimmune diseases. J Am Acad Dermatol 2012;67:924-30.
63. Angelucci E, Cocco A, Viscido A, Vernia P, Caprilli R: Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm Bowel Dis 2007;13:1059-61.
64. Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A: Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine. Clin Rheumatol 2008;27:377-80.
65. Wolf N, Quaranta M, Prescott NJ, et al: Psoriasis associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-6.
66. Cargill M, Schrodi SJ, Chang M, et al: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-90.
67. Fraga NA, Oliveira Mde F, Follador I, Rocha Bde O, Rego VR: Psoriasis and uveitis: a literature review. An Bras Dermatol 2012;87:877-83.
68. Demir HD, Kalkan G, Kurt S, Güneş A, Sezer E, Erkorkmaz Ü: Relationship between retinal sensitivity and disease activity in patients with psoriasis vulgaris. Clinics (Sao Paulo) 2015;70:14-7.
69. Goulding JM, Price CL, Defty CL, Hulangamuwa CS, Bader E, Ahmed I: Erectile dysfunction in patients with psoriazis: increased prevalence, an unmet need, and a chance to intervene. Br J Dermatol 2011;164:103-9.
70. Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, et al: Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol 2011;164:1247-55.
71. Machado-Pinto J, Diniz Mdos S, Bavoso NC: Psoriasis: new comorbidities. An Bras Dermatol 2016;91:8-14.
72. Sheu JJ, Wang KH, Lin HC, Huang CC: Psoriasis is associated with an increased risk of parkinsonism: a population-based 5-year follow-up study. J Am Acad Dermatol 2013;68:992-9.
73. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM: Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ 2013;347:f5961.
74. Russo PA, Ilchef R, Cooper AJ: Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004;45:155-9.
75. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ: Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002;47:512-8.
76. Higgins E: Alcohol, smoking and psoriasis. Clin Exp Dermatol 2000;25:107-10. 77. Poikolainen K, Reunala T, Karvonen J, Lauharanta J, Kärkkäinen P: Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ 1990; 300:780-3.
78. Naldi L, Chatenoud L, Linder D, et al: Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-7.
79. Radtke MA, Mrowietz U, Feuerhahn J, et al: Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis. J Dtsch Dermatol Ges 2015;13:674-90.
80. Wootton CI, Murphy R: Psoriasis in children: should we be worried about comorbidities? Br J Dermatol 2013;168:661-3.
81. Mrowietz U, Steinz K, Gerdes S: Psoriasis: to treat or to manage? Exp Dermatol 2014;23:705-9.
82. Friedewald VE, Cather JC, Gelfand JM, et al: AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008;102:1631-43.

APA	KALKAN G (2017). Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım. , 71 - 77.
Chicago	KALKAN Göknur Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım. (2017): 71 - 77.
MLA	KALKAN Göknur Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım. , 2017, ss.71 - 77.
AMA	KALKAN G Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım. . 2017; 71 - 77.
Vancouver	KALKAN G Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım. . 2017; 71 - 77.
IEEE	KALKAN G "Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım." , ss.71 - 77, 2017.
ISNAD	KALKAN, Göknur. "Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım". (2017), 71-77.

APA	KALKAN G (2017). Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım. Türkderm-Deri Hastalıkları ve Frengi Arşivi, 51(3), 71 - 77.
Chicago	KALKAN Göknur Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım. Türkderm-Deri Hastalıkları ve Frengi Arşivi 51, no.3 (2017): 71 - 77.
MLA	KALKAN Göknur Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım. Türkderm-Deri Hastalıkları ve Frengi Arşivi, vol.51, no.3, 2017, ss.71 - 77.
AMA	KALKAN G Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım. Türkderm-Deri Hastalıkları ve Frengi Arşivi. 2017; 51(3): 71 - 77.
Vancouver	KALKAN G Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım. Türkderm-Deri Hastalıkları ve Frengi Arşivi. 2017; 51(3): 71 - 77.
IEEE	KALKAN G "Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım." Türkderm-Deri Hastalıkları ve Frengi Arşivi, 51, ss.71 - 77, 2017.
ISNAD	KALKAN, Göknur. "Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım". Türkderm-Deri Hastalıkları ve Frengi Arşivi 51/3 (2017), 71-77.